National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

pNGVL3-hICD vaccine
A plasmid DNA cancer vaccine encoding the intracellular domain (ICD) of the HER-2/neu proto-oncogene. Upon administration and after cellular uptake by skin or muscle cells, the pNGVL3-hICD vaccine plasmid expresses the HER-2/neu protein, which, after intracellular processing, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-2. The HER-2/neu ICD protein is highly immunogenic and, as a subdominant epitope, may be associated with decreased immune tolerance. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:plevitrexed, plicamycin, plitidepsin, pneumococcal polyvalent vaccine, Pneumovax 23
Next:pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine, PNP-expressing ovine atadenovirus FP253, Pnu-Imune 23, polifeprosan 20 with carmustine implant, Polo-like kinase 1 inhibitor GSK-461364

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov